249 related articles for article (PubMed ID: 30945299)
1. The potential utility of melatonin in the treatment of childhood cancer.
Chao YH; Wu KH; Yeh CM; Su SC; Reiter RJ; Yang SF
J Cell Physiol; 2019 Nov; 234(11):19158-19166. PubMed ID: 30945299
[TBL] [Abstract][Full Text] [Related]
2. Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.
Reiter RJ; Rosales-Corral SA; Tan DX; Acuna-Castroviejo D; Qin L; Yang SF; Xu K
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420185
[TBL] [Abstract][Full Text] [Related]
3. A Review on Melatonin's Effects in Cancer: Potential Mechanisms.
Hanikoglu A; Kucuksayan E; Akduman RC; Ozben T
Anticancer Agents Med Chem; 2018; 18(7):985-992. PubMed ID: 29173185
[TBL] [Abstract][Full Text] [Related]
4. Melatonin in clinical oncology.
Bartsch C; Bartsch H; Karasek M
Neuro Endocrinol Lett; 2002 Apr; 23 Suppl 1():30-8. PubMed ID: 12019349
[TBL] [Abstract][Full Text] [Related]
5. Does the use of melatonin overcome drug resistance in cancer chemotherapy?
Asghari MH; Ghobadi E; Moloudizargari M; Fallah M; Abdollahi M
Life Sci; 2018 Mar; 196():143-155. PubMed ID: 29374563
[TBL] [Abstract][Full Text] [Related]
6. Melatonin's Antineoplastic Potential Against Glioblastoma.
Moretti E; Favero G; Rodella LF; Rezzani R
Cells; 2020 Mar; 9(3):. PubMed ID: 32138190
[TBL] [Abstract][Full Text] [Related]
7. Melatonin and its anti-glioma functions: a comprehensive review.
Maitra S; Bhattacharya D; Das S; Bhattacharya S
Rev Neurosci; 2019 Jul; 30(5):527-541. PubMed ID: 30645197
[TBL] [Abstract][Full Text] [Related]
8. The validity of melatonin as an oncostatic agent.
Panzer A; Viljoen M
J Pineal Res; 1997 May; 22(4):184-202. PubMed ID: 9247204
[TBL] [Abstract][Full Text] [Related]
9. Melatonin and cancer: From the promotion of genomic stability to use in cancer treatment.
Farhood B; Goradel NH; Mortezaee K; Khanlarkhani N; Najafi M; Sahebkar A
J Cell Physiol; 2019 May; 234(5):5613-5627. PubMed ID: 30238978
[TBL] [Abstract][Full Text] [Related]
10. Part-time cancers and role of melatonin in determining their metabolic phenotype.
Reiter RJ; Sharma R; Rodriguez C; Martin V; Rosales-Corral S; Zuccari DAPC; Chuffa LGA
Life Sci; 2021 Aug; 278():119597. PubMed ID: 33974932
[TBL] [Abstract][Full Text] [Related]
11. Melatonin: Current evidence on protective and therapeutic roles in gynecological diseases.
Hosseinzadeh A; Alinaghian N; Sheibani M; Seirafianpour F; Naeini AJ; Mehrzadi S
Life Sci; 2024 May; 344():122557. PubMed ID: 38479596
[TBL] [Abstract][Full Text] [Related]
12. Melatonin: new places in therapy.
Maharaj DS; Glass BD; Daya S
Biosci Rep; 2007 Dec; 27(6):299-320. PubMed ID: 17828452
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of melatonin in targeting molecular pathways of organ fibrosis.
Hosseinzadeh A; Pourhanifeh MH; Amiri S; Sheibani M; Irilouzadian R; Reiter RJ; Mehrzadi S
Pharmacol Rep; 2024 Feb; 76(1):25-50. PubMed ID: 37995089
[TBL] [Abstract][Full Text] [Related]
14. New perspectives in melatonin uses.
Carpentieri A; Díaz de Barboza G; Areco V; Peralta López M; Tolosa de Talamoni N
Pharmacol Res; 2012 Apr; 65(4):437-44. PubMed ID: 22311380
[TBL] [Abstract][Full Text] [Related]
15. Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives.
Grant SG; Melan MA; Latimer JJ; Witt-Enderby PA
Expert Rev Mol Med; 2009 Feb; 11():e5. PubMed ID: 19193248
[TBL] [Abstract][Full Text] [Related]
16. Melatonin: An important anticancer agent in colorectal cancer.
Mirza-Aghazadeh-Attari M; Mohammadzadeh A; Mostavafi S; Mihanfar A; Ghazizadeh S; Sadighparvar S; Gholamzadeh S; Majidinia M; Yousefi B
J Cell Physiol; 2020 Feb; 235(2):804-817. PubMed ID: 31276205
[TBL] [Abstract][Full Text] [Related]
17. Melatonin: new applications in clinical and veterinary medicine, plant physiology and industry.
Reiter RJ; Coto-Montes A; Boga JA; Fuentes-Broto L; Rosales-Corral S; Tan DX
Neuro Endocrinol Lett; 2011; 32(5):575-87. PubMed ID: 22167140
[TBL] [Abstract][Full Text] [Related]
18. Melatonin: adjuvant therapy of malignant tumors.
Dziegiel P; Podhorska-Okolow M; Zabel M
Med Sci Monit; 2008 May; 14(5):RA64-70. PubMed ID: 18443563
[TBL] [Abstract][Full Text] [Related]
19. Melatonin as a potential inhibitor of kidney cancer: A survey of the molecular processes.
Maleki Dana P; Reiter RJ; Hallajzadeh J; Asemi Z; Mansournia MA; Yousefi B
IUBMB Life; 2020 Nov; 72(11):2355-2365. PubMed ID: 32918860
[TBL] [Abstract][Full Text] [Related]
20. Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer.
Wojcik M; Krawczyk M; Wojcik P; Cypryk K; Wozniak LA
Curr Med Chem; 2017 Nov; 24(35):3829-3850. PubMed ID: 28721827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
